Is ADPT a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Adaptive Biotechnologies (ADPT) rests on clonoSEQ MRD volume and reimbursement: The core driver is clonoSEQ test volume, which grew about 41 percent year over year in the first quarter of 2026 to more than 32,000 tests. The bear case rests on aDPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. Analysts covering it publish targets from $20.00 to $25.00 against a $22.12 price, so even the professionals disagree by 22% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Adaptive Biotechnologies (NASDAQ: ADPT) runs an immune-medicine platform built around reading the genetics of the adaptive immune system. Its commercial engine is clonoSEQ, an FDA-cleared minimal residual disease (MRD) test that measures how many cancer cells remain in a patient during and after treatment, used mainly in blood cancers such as multiple myeloma, ALL, and CLL. The MRD segment now contributes roughly 95 percent of revenue and includes both clinical testing and pharma partnerships that use the platform in drug trials. A second Immune Medicine arm pursues drug discovery and includes a long-running collaboration with Genentech on neoantigen-directed T-cell therapies. The investment picture is a diagnostics growth story reaching an inflection point. First-quarter 2026 revenue rose about 35 percent year over year to roughly $70.9 million, MRD revenue grew about 53 percent, and clonoSEQ test volume climbed about 41 percent, prompting management to raise full-year MRD guidance toward roughly $260 million to $270 million. Losses have narrowed sharply and adjusted EBITDA is near breakeven, while a large cash balance funds the runway. In June 2026 the company announced a plan to separate the profitable, scaled MRD business from the earlier-stage Immune Medicine unit, a move that could reshape how the two pieces are valued.
The bull case: what would have to be true for $25.00
The most optimistic published target on ADPT is $25.00, +13.0% from the $22.12 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. clonoSEQ MRD volume and reimbursement
The core driver is clonoSEQ test volume, which grew about 41 percent year over year in the first quarter of 2026 to more than 32,000 tests. Expanding clinical guidelines, broader payer coverage, and adoption in additional blood-cancer indications support continued volume growth. Because MRD is roughly 95 percent of revenue, this is the metric that moves the story.
2. Pharma and biopharma partnerships
Beyond clinical testing, drugmakers use the MRD platform as a trial endpoint, and the company recognized milestone revenue tied to regulatory progress, including its first U.S. primary-endpoint milestone in early 2026. These partnerships add higher-margin, lumpier revenue on top of the recurring clinical test base. They also validate MRD as an accepted measure in oncology drug development.
3. Path to profitability
Net loss narrowed and adjusted EBITDA loss shrank toward breakeven in early 2026 as the MRD business scaled, a notable shift for a company that historically burned cash. Management has framed MRD as having reached profitability on a standalone basis. Continued operating leverage is central to the bull framing.
4. Planned MRD / Immune Medicine separation
In June 2026 the company announced plans to separate its scaled, profitable MRD business from the earlier-stage Immune Medicine unit, with a preferred path expected by year-end 2026. A split could let the market value a clean diagnostics grower on its own while isolating the drug-discovery risk. The structure and timing remain unsettled.
The bear case: what would have to be true for $20.00
The most pessimistic published target is $20.00, -9.6% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Adaptive Biotechnologies is worth if the risks below bite instead of the drivers above.
ADPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. The MRD diagnostics market is competitive, with Natera, Guardant Health, Exact Sciences, and NeoGenomics all pushing MRD and liquid-biopsy offerings, and reimbursement decisions can swing revenue. Pharma milestone revenue is lumpy and hard to forecast quarter to quarter. The announced business separation adds execution and structural uncertainty, and the Immune Medicine drug programs, including the Genentech-linked work, are early stage with binary outcomes. The stock has also been volatile, trading across a wide 52-week range.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ADPT already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ADPT
7 analysts cover ADPT, with an average target of $22.29 (+0.8% against $22.12) and a split of 7 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ADPT forecast and price target page.
How is ADPT valued? (as of July 2026)
Snapshot for ADPT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$250M
- Q1 2026 revenue: ~$70.9M (up ~35% YoY)
- 2026 MRD revenue guidance: ~$260M to $270M
- Q1 2026 net loss: ~$20M (improved from ~$30M)
- Cash and investments: ~$237M
- Market cap: ~$3.6B
As of July 2026 ADPT trades at a high revenue multiple typical of a growing, near-breakeven diagnostics company rather than on earnings, since it remains unprofitable on a consolidated basis. The large cash balance relative to burn gives multi-year runway. Valuation hinges heavily on continued MRD volume growth and how the market treats a potential separation.
How do you decide if ADPT is a buy?
Rather than asking whether ADPT is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ADPT indirectly through an index or sector ETF before adding more.
What would change your mind on ADPT
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: clonoSEQ MRD volume and reimbursement stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: aDPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ADPT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ADPT against your real portfolio and see your actual exposure before deciding.
Investing in Adaptive Biotechnologies with AI
Connect the broker you already use and ask Walnut's AI how ADPT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is ADPT a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on clonoSEQ MRD volume and reimbursement, with revenue (ttm) at ~$250M. The bear case rests on aDPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. Analysts covering it are spread from $20.00 to $25.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ADPT?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. ADPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $20.00, -9.6% from the $22.12 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for ADPT?
+
clonoSEQ MRD volume and reimbursement. The core driver is clonoSEQ test volume, which grew about 41 percent year over year in the first quarter of 2026 to more than 32,000 tests. The most optimistic analyst target on ADPT is $25.00, +13.0% from the $22.12 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ADPT?
+
ADPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. The MRD diagnostics market is competitive, with Natera, Guardant Health, Exact Sciences, and NeoGenomics all pushing MRD and liquid-biopsy offerings, and reimbursement decisions can swing revenue. Pharma milestone revenue is lumpy and hard to forecast quarter to quarter. The announced business separation adds execution and structural uncertainty, and the Immune Medicine drug programs, including the Genentech-linked work, are early stage with binary outcomes. The stock has also been volatile, trading across a wide 52-week range. The most pessimistic published target is $20.00, -9.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Adaptive Biotechnologies do?
+
Adaptive Biotechnologies (NASDAQ: ADPT) runs an immune-medicine platform built around reading the genetics of the adaptive immune system.
What would have to change for ADPT to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (clonoSEQ MRD volume and reimbursement) stalling in the reported numbers rather than in the narrative, the risk above (aDPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Adaptive Biotechnologies (ADPT) do?
+
It operates an immune-medicine platform that reads the genetics of the adaptive immune system. Its main commercial product is clonoSEQ, an FDA-cleared minimal residual disease (MRD) test used to monitor remaining cancer cells, primarily in blood cancers. A separate arm pursues immune-based drug discovery.
What is clonoSEQ and why does it matter to ADPT?
+
clonoSEQ is Adaptive's MRD diagnostic that measures how many cancer cells remain during and after treatment. It drives roughly 95 percent of the company's revenue, so its test volume, reimbursement, and clinical adoption are the central factors in the business.
Is ADPT profitable?
+
As of July 2026 the company still reports a consolidated net loss, though it has narrowed sharply and adjusted EBITDA is near breakeven. Management has described the standalone MRD business as having reached profitability, while the broader company is not yet profitable.
Walnut is informational, not investment advice, and gives no verdict on ADPT. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.